Q2 2025 Syngene International Ltd Earnings Call Transcript
Key Points
- Syngene International Ltd (BOM:539268) reported a sequential revenue growth of 13% in the second quarter, indicating positive momentum.
- The company is seeing increased interest from large and medium-sized BioPharma clients, particularly in biologics and small molecule process development projects.
- Syngene International Ltd (BOM:539268) successfully concluded around 60 audits in the first six months, a 35% increase year over year, reflecting strong client engagement.
- The company is investing in expanding its capabilities in biologics, with new manufacturing capacity expected to come online in the second half of the year.
- Syngene International Ltd (BOM:539268) is focusing on dual sourcing and supply chain resilience, offering clients alternatives to China, which is gaining traction with about a third of clients opting for this option.
- Revenue from operations for the quarter was down 2% year on year, and 3% in constant currency terms.
- Operating EBITDA decreased by 4% to INR245 crore, and profit after tax was down 9% year on year.
- The company experienced a decline in raw material costs by 11% due to a shift in revenue mix, but staff costs increased by 12% year on year.
- Other operating costs increased by 16% year on year due to maintenance and expansion of facilities.
- The company expects revenue growth for the year to be at the lower half of its guidance range, indicating potential challenges in achieving higher growth targets.
Ladies and gentlemen, good day and welcome to Syngene International second quarter FY2025 financial results conference call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Ms. Nandini Agarwal. Thank you, and over to you, ma'am.
Thank you and good afternoon to everyone. Thank you for joining us on this call to discuss in June second quarter and half year results for financial year 2025 to discuss the financial and business performance for the period we have on this call with us today. Mr Jonathan Hunt, Syngene's Managing Director and Chief Executive Officer; and Mr Sibaji Biswas, Executive Director and Chief Financial Officer.
After the opening remarks, Jonathan and Sibaji will be happy to answer any questions you might have before we begin. I would like to caution that comments made during this conference call today will contain certain forward-looking statements and must be viewed in relation to the risk pertaining to the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
